We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
- Authors
Grady, Deborah; Cauley, Jane A; Geiger, Mary Jane; Kornitzer, Marcel; Mosca, Lori; Collins, Peter; Wenger, Nanette K; Song, Jingli; Mershon, John; Barrett-Connor, Elizabeth; Raloxifene Use for The Heart Trial Investigators
- Abstract
In the Raloxifene Use for The Heart trial, 10 101 postmenopausal women with coronary heart disease (CHD) or multiple CHD risk factors were randomly assigned to 60 mg/d raloxifene or to placebo and followed for a median of 5.6 years. Raloxifene, a selective estrogen receptor modulator, was found to reduce the risk of invasive breast cancer and vertebral fractures but not the risk of cardiovascular events. Here, we provide further details about breast cancer incidence by tumor characteristics, duration of treatment, and subgroup.
- Publication
Journal of the National Cancer Institute, 2008, Vol 100, Issue 12, p854
- ISSN
1460-2105
- Publication type
Journal Article
- DOI
10.1093/jnci/djn153